Protocol Ledger

NCT03736889 · Phase II · RECRUITING

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Interventional Phase II clinical trial protocol NCT03736889 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-19 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03736889
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03736889
Protocol FieldVerified Registry Value
NCT IdentifierNCT03736889
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2018-09-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI